Hualan Biological Vaccine Inc. (SHE:301207)
China · Delayed Price · Currency is CNY 19.42
+0.36 (1.89%)
At close: Mar 6, 2026
Hualan Biological Vaccine Revenue
Hualan Biological Vaccine had revenue of 746.03M CNY in the quarter ending September 30, 2025, a decrease of -19.07%. This brings the company's revenue in the last twelve months to 976.44M, down -40.80% year-over-year. In the year 2024, Hualan Biological Vaccine had annual revenue of 1.13B, down -53.21%.
Revenue (ttm)
976.44M
Revenue Growth
-40.80%
P/S Ratio
11.83
Revenue / Employee
1.31M
Employees
748
Market Cap
11.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13B | -1.28B | -53.21% |
| Dec 31, 2023 | 2.41B | 584.79M | 32.03% |
| Jan 1, 2023 | 1.83B | -4.17M | -0.23% |
| Jan 1, 2022 | 1.83B | -596.52M | -24.59% |
| Dec 31, 2020 | 2.43B | 1.38B | 131.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Chengzhi | 11.53B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |
| Mabwell (Shanghai) Bioscience | 662.52M |
| HitGen | 525.57M |